<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporin-A</z:chebi> (CsA) was given to 22 patients who received allogeneic bone marrow transplants as therapy for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The drug was given daily for 180 days starting with the day of marrow infusion </plain></SENT>
<SENT sid="2" pm="."><plain>Engraftment was not impaired and myelotoxicity was not observed </plain></SENT>
<SENT sid="3" pm="."><plain>Cutaneous <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) developed in five patients and <z:hpo ids='HP_0000001'>all</z:hpo> either spontaneously resolved or promptly responded to therapy with steroids </plain></SENT>
<SENT sid="4" pm="."><plain>Five patients developed systemic GVHD and <z:hpo ids='HP_0000001'>all</z:hpo> responded to therapy with steroids, but only two survived </plain></SENT>
<SENT sid="5" pm="."><plain>Interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo> was seen in six patients and was fatal in <z:hpo ids='HP_0000001'>all</z:hpo> of them </plain></SENT>
<SENT sid="6" pm="."><plain>Liver function abnormalities were seen in 14 patients but could not positively be correlated with CsA administration </plain></SENT>
<SENT sid="7" pm="."><plain>Renal function abnormalities were seen in 17 patients </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="1" ids="2682">Amphotericin-B</z:chebi> therapy contributed significantly to the <z:hpo ids='HP_0000083'>renal failure</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Serum levels of CsA, measured by radioimmunoassay, could not be correlated with the presence of liver or renal function abnormalities </plain></SENT>
<SENT sid="10" pm="."><plain>Overall survival so far has been 50.0% </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">Second malignancies</z:e> were not observed, but one patient relapsed with <z:hpo ids='HP_0001909'>leukemia</z:hpo> at 343 days </plain></SENT>
</text></document>